Brief: Abpro Finalizes Strategic Partnership With Celltrion For Worldwide Development And Commercialization Of Cancer Treatment Bispecific Antibody
21/09/2022 14:34
Sept 21 (Reuters) - Celltrion Inc 068270.KS :
* ABPRO FINALIZES STRATEGIC PARTNERSHIP WITH CELLTRION FOR
WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION OF A CANCER
TREATMENT BISPECIFIC ANTIBODY
Source text for Eikon: ID:nBw8C4GFRa
Further company coverage: 068270.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares